Construction of AstraZeneca’s new global and R&D headquarters in Cambridge should have been completed last autumn – but builders are struggling to meet a revised deadline of May 2019.
In another example of the pharma industry embracing generative artificial intelligence (genAI), Boehringer Ingelheim will use technology developed by IBM to rev up antibod
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio
